Compared to Estimates, United Therapeutics (UTHR) Q1 Earnings: A Look at Key Metrics

United Therapeutics (UTHR) reported $677.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 33.7%. EPS of $6.17 for the same period compares to $4.86 a year ago.

The reported revenue represents a surprise of +7.96% over the Zacks Consensus Estimate of $627.72 million. With the consensus EPS estimate being $5.63, the EPS surprise was +9.59%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how United Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Rest-of-World: $36.20 million versus $35.73 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.7% change.
  • Revenues- United States: $641.50 million versus $591.44 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +36.6% change.
  • Revenues- Unituxin: $58.40 million versus the seven-analyst average estimate of $50.61 million. The reported number represents a year-over-year change of +18.9%.
  • Revenues- Remodulin: $128 million versus $116.55 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +5.4% change.
  • Revenues- Orenitram: $106.20 million versus $91.76 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +20.4% change.
  • Revenues- Tyvaso: $227.50 million versus $360.84 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -4.6% change.
  • Revenues- Adcirca: $6.40 million versus $5.15 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -12.3% change.
View all Key Company Metrics for United Therapeutics here>>>

Shares of United Therapeutics have returned +2.5% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

United Therapeutics Corporation (UTHR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.